Eledon Pharmaceuticals, Inc. (ELDN) Stock

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. is led by CEO David-Alexandre C. Gros, employs 31 people, headquartered in US, publicly traded since 2014.

Eledon Pharmaceuticals, Inc. (ELDN) stock trades at $2.30 with a market capitalization of $186.90M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.53, reflecting a net loss over the last twelve months, price-to-book of 3.95, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.35 and $4.60, and currently trades 50.0% below its 52-week high.

On profitability, Eledon Pharmaceuticals, Inc. generates a return on equity (ROE) of -136.45% (negative, reflecting a net loss), return on capital employed of -74.02%.

Eledon Pharmaceuticals, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Eledon Pharmaceuticals, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-46.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-98.0M.

Borrowings fell from $3.0M to $1.0M, cash from operations was $-62.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -377.0% over five years, and was -56.8% in the most recent year.

The share price itself has compounded at -14.6% a year over five years, 30.8% over three, 22.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Eledon Pharmaceuticals, Inc. (ELDN) — frequently asked questions